March 04, 2015 6:10 PM ET


Company Overview of Cylene Pharmaceuticals, Inc.

Company Overview

Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery and development of small molecule drugs for the treatment of cancer deceases. The company’s products include oral inhibitors of the cancer-linked serine/threonine protein kinases (CK2 and Pim); and oral agents that activate p53 via modulation of RNA Polymerase I activity in the upstream ribosome biogenesis pathway. Cylene Pharmaceuticals, Inc. was formerly known as Cyternex, Inc. and changed its name in October 2003. The company was founded in 1997 and is based in San Diego, California.

5820 Nancy Ridge Drive

Suite 200

San Diego, CA 92121

United States

Founded in 1997





Key Executives for Cylene Pharmaceuticals, Inc.

Co-Founder, Senior Vice President of Medical Affairs, Director and Member of Scientific Advisory Board
Age: 66
Senior Vice President of Clinical & Regulatory Affairs
Senior Vice President of Chemistry & Pharmaceutical Operations
Vice President of Research & Business Development
Vice President of Research
Compensation as of Fiscal Year 2014.

Cylene Pharmaceuticals, Inc. Key Developments

Cylene Pharmaceuticals, Inc. and TetraGene LLC Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies

Cylene Pharmaceuticals, Inc. announced that it has entered into an exclusive, worldwide Option and License Agreement that will allow TetraGene LLC to advance the development of Quarfloxin and Cylene's associated anticancer quadruplex-targeting technologies. Cylene will receive an upfront fee, as well as potential milestone payments and royalties on product sales for the exclusive license. TetraGene is developing small molecule drugs aimed at highly validated cancer-causing genes, by directly targeting G-quadruplex structures in genomic DNA. TetraGene has the option to acquire worldwide rights to the technologies licensed from Cylene, which include the Phase II compound Quarfloxin and several registered patents. Quarfloxin has been demonstrated to be safe and well-tolerated in Phase I clinical trials. Cylene Pharmaceuticals is a clinical-stage private company developing small molecule drugs against newly validated targets in essential cancer pathways. The company's Pol I program provides a non-genotoxic mechanism for activating p53 to kill cancer cells. Cylene's leadership in exploiting CK2 pathways enables rational drug combinations for improved treatment outcomes against many cancer indications. Cylene's unique approaches deliver innovative cancer agents that can enable pharmaceutical companies to expand their portfolios and extend the efficacy, lifecycle and reach of current cancer therapeutics.

Similar Private Companies By Industry

Company Name Region
LifeGen Technologies LLC United States
Plant Sensory Systems, LLC United States
Bio-Defense Research Group, Inc. United States
Pioneer Surgical Orthobiologics, Inc. United States
Online Disruptive Technologies, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cylene Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at